Development of Sanofi Pasteur tetravalent dengue vaccine

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 696-705

  Guy, Bruno ^a   Saville, Melanie ^a   Lang, Jean ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Dengue; Development; Human; Immunity; Vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; DENDRITIC CELL; DENGUE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESEARCH; ENVELOPE GENE; FLAVIVIRUS; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; NONHUMAN; PHENOTYPE; REVIEW; VACCINATION; VIREMIA; VIRUS IMMUNITY; VIRUS VIRULENCE;

EID: 78649384507     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12739     Document Type: Review

References (46)

1. Halstead SB. Dengue. Lancet 2007; 370:1644-52.
2. Reiter P. Yellow fever and dengue: a threat to Europe? Euro Surveill 2010; 15:19509.
3. Raviprakash K, Defang G, Burgess T, Porter K. Human Vaccines 2009; 5:520-8.
4. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-28.
5. Guy B, Almond JW. Towards a dengue vaccine: Progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008; 31:239-52.
6. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73:3095-101.
7. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74:5477-85.
8. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-49.
9. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 8:4761-75.
10. Barban V, Girerd Y, Aguirre M, Gulia S, Pétiard F, Riou P, et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007; 25:2941-50.
11. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004; 78:1032-8.
12. Miller BR, Atkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 1988; 32:227-34.
13. Vlaycheva LA, Chambers TJ. Neuroblastma cell-adapted yellow fever 17D virus: Characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol 2002; 76:6172-84.
14. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 2001; 75:3501-8.
15. Palmer DR, Sun P, Celluzzi C, Bisbing J, Pang S, Sun W, et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 2005; 79:2432-9.
16. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005; 72:74-81.
17. Deauvieau F, Sanchez V, Balas C, Kennel A, de Montfort A, Lang J, et al. Innate immune responses in human dendritic cells upon infection by chimeric Yellow fever Dengue vaccines serotype 1 to 4. Am J Trop Med Hyg 2007; 76:144-54.
18. Monath TP, Myers GA, Beck RA, Knauber M, Scappaticci K, Pullano T, et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005; 33:131-44.
19. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
20. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69:12-6; Erratum in: Am J Trop Med Hyg 2004; 70:336.
21. Putnak RJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-52.
22. Guy B, Barban V, Mantel M, Aguirre M, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80:302-11.
23. Higgs S, Vanlandingham DL, Klingler KA, McElroy KL, McGee CE, Harrington L, et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg 2006; 75:986-93.
24. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363:2073-5.
25. Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, et al. Recombination and flavivirus vaccines: a commentary. Vaccine 2005; 23:2956-8.
26. Hombach J, Kurane I, Wood D. Arguments for live flavivirus vaccines. Lancet 2004; 364:498-9.
27. Taucher C, Berger A, Mandl CW. A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination. J Virol 2010; 84:599-611.
28. McGee CE, Tsetsarkin K, Vanlandingham DL, McElroy KL, Lang J, Guy B, et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008; 197:686-92.
29. McGee CE, Lewis MG, Claire MS, Wagner W, Lang J, Guy B, et al. Recombinant chimeric virus with wildtype dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008; 197:693-7.
30. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:6077-82.
31. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccine 2006; 2:60-7.
32. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201:370-7.
33. Crevat D, Reynolds D, Langevin E, Capeding MR. Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Flavivirus-naive and immune Pediatric Populations with Two Vaccination Regimens. Am J Trop Med Hyg 2009; 81:113.
34. Forrat R, Poo JL, Galán Herrera JF. Immune Response to Tetravalent Dengue Vaccination in Mexican subjects: the Effects of Yellow Fever Vaccination. Am J Trop Med Hyg 2008; 79:114.
35. th International Congress on Infectious Diseases 2008; Kuala Lumpur, Malaysia.
36. th ASTM&H annual meeting Washington DC 2009.
37. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36.
38. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265:739-41.
39. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke D. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
40. Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Libraty DH, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 2002; 185:1697-703.
41. + T Cells to Heterologous Serotypes. J Immunol 2005; 175:2676-83.
42. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26:5712-21.
43. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9:921-7.
44. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563-74.
45. Edelman R, Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Summary of a WHO technical consultation. Vaccine 2008; 26:4113-9.
46. Thomas SJ, Hombach J, Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009; 27:355-68.